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Abstract
Background: The significant increase in the average life expectancy has increased the societal challenge of
managing serious age-related diseases, especially cancer and cardiovascular diseases. A routine check by a general
practitioner is not sufficient to detect incipient cardiovascular disease.
Design: Population-based randomized clinically controlled screening trial.
Methods: Participants: 45,000 Danish men aged 65–74 years living on the Island of Funen, or in the surrounding
communities of Vejle and Silkeborg. No exclusion criteria are used.
Interventions: One-third will be invited to cardiovascular seven-faceted screening examinations at one of four
locations. The screening will include: (1) low-dose non-contrast CT scan to detect coronary artery calcification and
aortic/iliac aneurysms, (2) brachial and ankle blood pressure index to detect peripheral arterial disease and
hypertension, (3) a telemetric assessment of the heart rhythm, and (4) a measurement of the cholesterol and
plasma glucose levels. Up-to-date cardiovascular preventive treatment is recommended in case of positive findings.
Objective: To investigate whether advanced cardiovascular screening will prevent death and cardiovascular events,
and whether the possible health benefits are cost effective.
Outcome: Registry-based follow-up on all cause death (primary outcome), and costs after 3, 5 and 10 years
(secondary outcome).
Randomization: Each of the 45,000 individuals is, by EPIDATA, given a random number from 1–100. Those
numbered 67+ will be offered screening; the others will act as a control group.
Blinding: Only those randomized to the screening will be invited to the examination;the remaining participants will not.
Numbers randomized: A total of 45,000 men will be randomized 1:2.
Recruitment: Enrollment started October 2014.
Outcome: A 5 % reduction in overall mortality (HR = 0.95), with the risk for a type 1 error = 5 % and the risk for a type II
error = 80 %, is expected. We expect a 2-year enrollment, a 10-year follow-up, and a median survival of 15 years among
the controls. The attendance to screening is assumed to be 70 %.
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Discussion: The primary aim of this so far stand-alone population-based, randomized trial will be to evaluate the
health benefits and costeffectiveness of using non-contrast full truncus computer tomography (CT) scans (to measure
coronary artery calcification (CAC) and identify aortic/iliac aneurysms) and measurements of the ankle brachial blood
pressure index (ABI) as part of a multifocal screening and intervention program for CVD in men aged 65–74.
Attendance rate and compliance to initiated preventive actions must be expected to become of major importance.
Trial registration: Current Controlled Trials: ISRCTN12157806 (21 March 2015).
Keywords: Cardiovascular prevention, Screening, Aortic aneurysm, Coronary calcium score, Atrial fibrillation, Peripheral
arterial disease, Benefit, Cost effectiveness, Public health
Background
Although cardiovascular diseases (CVDs) have decreased
during the last two decades, CVDs are still one of the
most predominant causes of morbidity and mortality in
the western world, including Denmark, where approxi-
mately 420,000 people have recognized symptoms [1, 2].
Due to an aging population, the decline in CVD inci-
dence observed during the past decades has not led to a
decrease in hospital admissions and health-related costs
due to CVDs. The size of the Danish population is about
5.5 million, and approximately 14,000 people die annu-
ally from CVDs, compared to 16,000 deaths caused by
cancer, the most common cause of death. The annual
CVD-attributable costs of hospital admissions amount
to DKK 4.6 billion, while pharmaceuticals amount to
DKK 2.4 billion. In addition, an unknown number of
visits to the general practitioner (GP) occur.
Screening for CVD has been discussed intensively [3, 4].
Ultrasound-based screening for abdominal aortic aneurysm
(AAA) seems to reduce mortality [5], while evidence sup-
porting screening for ischemic heart disease is lacking.
Population-based screening of high-risk individuals with
the intention to initiate preventive treatment has not been
associated with a reduction in all-cause or cardiovascular
mortality [6, 7].
To assess the risk and target preventive interventions,
global risk scores, such as the HeartScore and the
Framingham Risk Score, are recommended. These
scores are useful for combining individual risk factors
(age, gender, diabetes, smoking, blood pressure, and
cholesterol levels) into a single quantitative risk estimate.
In Europe, individuals with a 10-year risk of CVD death
≥5 % qualify for primary prevention, including lifestyle
intervention and, in some cases, drug treatment. In indi-
viduals with a CVD death risk ≥10 %, drug treatment is
more frequently recommended. However, in individuals
older than 65 years, the risk scores should be interpreted
more leniently due to a lack of evidence [8, 9]. Guideline-
based recommendations on interventions for the elderly
population are lacking despite the fact that more than
95 % of CVD deaths occur in people more than 65 years
old. The European Guidelines on cardiovascular disease
prevention 2012 acknowledge that “Prevention of CVD
ideally starts during pregnancy and lasts until the end of
life”, and states that “Studies have shown that preventive
measures (i.e. BP lowering and smoking cessation) are
beneficial up to advanced age.” However, elderly people
have an increased risk of non-cardiovascular disease and
all-cause death, and the guideline states “In persons
older than 60, these thresholds should be interpreted
more leniently, because their age-specific risk is nor-
mally around these levels, even when other cardiovascu-
lar risk factor levels are ‘normal’.”
Consequently, the primary aim of this so far stand-alone
population-based, randomized trial will be to evaluate the
health benefits and costeffectiveness of using non-contrast
full truncus computer tomography (CT) scans (to measure
coronary artery calcification (CAC) and identify aortic/iliac
aneurysms) and measurements of the ankle brachial blood
pressure index (ABI) as part of a multifocal screening and
intervention program for CVD in men aged 65–74. Sec-
ondary aims will be the prospective observational studies
of the prognostic importance of the calcification scores of
the carotid, aorta, iliac, and femoral arteries, as well as the
pathophysiological and translational biomarker studies
that are made possible by biobanking.
Calcified arteries: carotid, coronary, aortic, iliac, and
femoral arteries
A low-dose CT scan without contrast can visualize calci-
fications of any artery. This technology was especially
developed to evaluate for CAC, and several studies have
demonstrated that the CAC scores improve the discrim-
ination and reclassification of CAD above and beyond
the traditional risk factors [10–14]. The prognostic value
of grading calcifications of the carotid, aortic, iliac, and
common femoral arteries is unknown. A few random-
ized clinical trials (RCTs) have evaluated the effect of
statin treatment in asymptomatic patients with CAC,
but the results are inconclusive [15, 16].
Aneurysms
Level A evidence has shown that ultrasound-based
screening for AAA in men aged 65–74 years in
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Denmark reduces AAA mortality by 66 % at a cost of
DKK 1,500 to 5,500 per life-year gained [5, 17], and the
procedure is being implemented in the UK, USA, and
Sweden. By extending a non-contrast CT screening for
CAC to include the abdominal aorta, the screening for
AAA will incur a small additional cost, but it will also
uncover thoracic aortic aneurysms (TAAs) and iliac an-
eurysms (IAs). Modern endovascular treatment may
provide a low-risk intervention for these aneurysms.
AAA, TAA, and IA will be diagnosed with close to
100 % sensitivity and specificity by the extended use of a
non-contrast CT scan.
Peripheral arterial disease (PAD)
Studies indicate that approximately 5–10 % of men
above 60 years old show signs of PAD and the propor-
tion increases with age. Although three of four patients
are asymptomatic, approximately 25–30 % of the pa-
tients with PAD will die from CVD within a 5-year
period regardless of whether they exhibit symptoms or
not. An even higher proportion will need hospitalization
due to CVD [18]. Efficient prevention of CVD-specific
deaths, amputations, and other CVD events can be
achieved through smoking cessation, exercise, a healthful
diet, aspirin, lipid-lowering treatment, and treatment of
elevated blood pressure [19, 20].
Hypothesis
The primary hypothesis is that the offer of an extensive
cardiovascular screening and intervention program ful-
fills the WHO criteria for screening [21], especially con-
cerning the significance of the diseases, the treatment
benefits, and the cost effectiveness from a national
health care system perspective.
Objectives
The primary objective of the study is to establish the
health effect and the second is to evaluate the cost ef-
fectiveness of an advanced cardiovascular screening and
intervention program for men aged 65–74 years in a
randomized controlled trial.
Methods/design
This is a population-based randomized clinically con-
trolled screening trial, randomizing two thirds of the
study participants to usual care without any screening
(control group), while one third of the participants are
invited to screening of CAC, aneurysms, PAD, atrial fib-
rillation, and traditional risk factors (screening group).
The control group will not be informed about the trial.
Power calculations
A total of 45,000 (about 3x14,647) men are needed to
detect a 5 % reduction in overall mortality (hazard ratio
(HR) = 0.95) with the risk for a type 1 error = 5 % and
the risk for a type II error = 80 %. We expect a 2-year
enrollment, a 10-year follow-up, and a median survival
of 15 years among the controls. The randomization ratio
will be 1 invited:2 controls [22]. The attendance is as-
sumed to be 70 % [5, 10] (Fig. 1).
Randomization
Information on all people in the source population (civil
registration number, name, and address) will be deliv-
ered by the civil personal registry (CPR). Randomization
will be performed in EPIDATA by prospectively provid-
ing each individual a random number from 1–100.
Those numbered 68–100 will be invited to participate in
the screening program.
Inclusion and exclusion criteria
The inclusion criteria are people of male gender, aged
between 65 and 74 years, and who are living in the in-
volved communities. There are no exclusion criteria.
Screening
The central project secretariat will invite the selected in-
dividuals. A small questionnaire concerning life style,
medical history, and the quality of life (QoL) a.o. will be
enclosed in the invitation. Web-based booking is pos-
sible and recommended, but appointments can also be
done by email or phone.
At attendance, informed consent will be obtained to-
gether with the questionnaire, weight, height, and waist
circumference. HbA1c, lipid parameters, hemoglobin,
creatinine kinase (CK), and alanine aminotransferase
(ALAT) are measured and biobank blood samples are
stored. Bilateral blood pressure will be recorded three
times after 5 minutes of supine rest. The ankle blood
pressure will be measured concurrently with the brachial
blood. The CT scan will cover the area from the man-
dibular bone distally to the proximal third of the femur.
Calcium scores for the coronaries will be calculated. The
aorta will be visualized, and in the case of dilation, the
maximal perpendicular outer to outer anteriorposterior
(AP) and tranverse diameter will be measured. If no dila-
tion is found, the AP diameter will be measured at five
sites (ascending aorta, aortic arch, descending aorta, ab-
dominal aorta just above the bifurcation, and iliac ar-
tery). The heart rhythm shown by the telemetry of the
CT scanner is noted. Data is entered in a web database
at the screening site.
Two days later the blood tests are loaded to the web-
based database. A program evaluates all the individual
findings, and sends lists to the secretary addressing
which actions are to be taken (Fig. 2).
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Fig. 2 Algorithm after attending screening. Supplemental algorithm for aneurysms; see Table 1
Fig. 1 Expected flow chart of the men included in the DANCAVAS trial
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Prophylactic actions after screening
For all screening locations, if the CAC is above the me-
dian or if ascending TAA, Arcus TAA, descending TAA,
AAA, IA (definition: diameter ≥ 45, 40, 35, 30 and
20 mm, respectively) or PAD (Def.: ABI ≤ 0.9 or > 1.4) is
detected, the patient will be informed at a follow-up visit
of the finding and its potential implications. At this visit,
the patient will be recommended suitable prophylactic
measures, including smoking cessation, walking/exercise,
a low-fat diet, and starting treatment with aspirin
75 mg/day (except in patients with anemia (hemoglobin
below 6 mmol/L), patients with gastric ulcer within the
prior three months, and patients with a daily use of
non-steroidal anti-inflammatory drugs) and atorvastatin
40 mg/day (except in patients with elevated CK or ALAT,
five and three times above normal reference level, respect-
ively). If the ascending aorta, aortic arch, descending aorta,
abdominal aorta, and iliac artery exceed a diameter of 65,
60, 55, 55, or 30 mm, respectively, the patient will be re-
ferred for a contrast-enhanced CT scan followed by a vas-
cular surgical assessment at one of the four involved
vascular centers that use these uniform size thresholds for
the repair of asymptomatic aneurysms [23]. If an aneurysm
is detected, but without an indication for surgery, biannual
to every second year check-ups including a CT scan will be
offered according to the algorithm shown in Table 1. Pa-
tients with prior unknown atrial fibrillation are prescribed
anticoagulants and referred to echocardiography (Fig. 2).
If no positive findings (CAC above the median,
aneurysm, PAD, or atrial fibrillation) are detected, the par-
ticipants will be informed of the findings by ordinary mail.
Independent of the above findings, the patients will be
encouraged to contact their GP for further assessment if
potential undiagnosed hypertension (systolic blood pressure
≥160 mmHg) [24], diabetes mellitus (HbA1c ≥48 mmol/
mol) [25], or significant isolated hypercholesterolemia (total
cholesterol ≥8.0 mmol/L) are observed, as possible continu-
ous medical treatments will be better managed by the GPs.
The GPs will be informed electronically of all negative
and positive results and the initiated actions (Fig. 2).
Annual follow-up
Annual follow-up will be conducted through data extrac-
tion from registries and the life style questionnaires that will
be sent to the participants. Prescription records that show
the implementation of pharmacological interventions, as
well as hospitalization records and disease-specific mortal-
ity data, will be collected from the government maintained
nationwide registries, as no delivery of prescribed medi-
cations, hospitalizations, and deaths is possible in Denmark
without being recorded in these registries. These indi-
vidual-based data are available for researchers. Conse-
quently, these registries have been continuously subjected
to an in-depth validation process and have been proven
valid regarding data on CVD and mortality [26–32].
Patients with aneurysms that do not exceed the size
threshold for a vascular surgical evaluation referral will be
offered a biannual to every second year CT (Table 1). The
attendance rates for these control scans are documented
in the RCTs performed previously in Denmark to be 95 %.
Pilot studies
Supervised measurements of the CAC scoring, the diame-
ters of thoracoabdominal aorta and iliac arteries, and the
ABI will be performed by senior examiners in the first 50
cases, followed by interobserver validation in the next 50
cases. If the mean differences in the CAC score, aortic
diameter, and ABI are below 10 %, 2 mm, and 15 %, re-
spectively, unsupervised examination will be allowed;
otherwise, the training and validation procedure will be
repeated. After the first 500 examinations, re-validation of
the interobserver agreement will be repeated.
The age-specific median for the CAC score will be
established after the first 500 examinations. Non-
contrast CT and ultrasound will be performed in the
Table 1 Algorithm after diagnosing an aneurysm in the
DANCAVAS trial
Ascending aortic aneurysm:
+65 mm: Contrast-enhanced CT scan and referral for surgical evaluation
50–64 mm: Echocardiography for bicuspid aortic valve (BAV):
+ BAV: If so, contrast-enhanced CT scan and referral for surgical evaluation
- BAV: Annual non contrast-enhanced CT scan
45–49 mm: Non contrast-enhanced CT scan every 2 years
Aortic arch aneurysm
+60 mm: Contrast-enhanced CT scan and referral for surgical evaluation
55–59 mm: Biannual non contrast-enhanced CT scan
50–54 mm: Annual non contrast-enhanced CT scan
35–49 mm: Non contrast-enhanced CT scan every 2 years
Descending aortic aneurysm
+55 mm: Contrast-enhanced CT scan and referral for surgical evaluation
50–54 mm: Biannual non contrast-enhanced CT scan
45–49 mm: Annual non contrast-enhanced CT scan
35–44 mm: Non contrast-enhanced CT scan every 2 years
Abdominal aortic aneurysm
+55 mm: Contrast-enhanced CT scan and referral for surgical evaluation
50–54 mm: Biannual non contrast-enhanced CT scan
45–49 mm: Annual non contrast-enhanced CT scan
30–44 mm: Non contrast-enhanced CT scan every 2 years
Iliac aneurysm
Confirmation of diagnosis by vascular surgeon (JL)
+30 mm: Contrast-enhanced CT scan and referral for surgical evaluation
25–29 mm: Annual non contrast-enhanced CT scan
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first 500 men, and using ultrasound as the gold standard,
the concordance between non-contrast CT and ultra-
sound in the detection of AAA will be analyzed.
The screening method for hypertension (after 5 mi-
nutes of supine rest) will be validated in the first 500
men with blood pressure measurements of patients in a
seated position in an isolated room as the gold standard.
In both cases, the blood pressure will be measured three
times. In addition, 24 hour blood pressure measure-
ments will be taken in a subgroup.
Personal contact information, the randomization process,
the central secretary administration, staff education, the
acceptance rates to the screening invitation, the
standardization of screening and treatment protocols, the
systems for collecting initial and follow-up data, the re-
sponse rates to the questionnaires, quality control of the
procedures, and the organization of trial data will be
tested and evaluated in the first 2,000 male residents of
Odense recruited into the study.
Outcome variables and statistical analyses
The entire study population, the controls as well as the
screening group, will be monitored for a period of
10 years. The primary outcome variable is overall mor-
tality, while hospitalizations and deaths from cardiovas-
cular diseases (cerebrovascular, cardiac, aneurysm, or
other vascular) are the secondary endpoints. Specific
causes of deaths and hospitalizations will be analyzed re-
spectively, and not as composite endpoints.
The endpoints are compared for the two groups using
a Cox proportional hazards regression analysis by the
“intention-to-treat” principle.
Cancer incidence and cancer-related deaths will be
compared between the two groups as a safety outcome
as a possible consequence of mass CT scanning.
An independent endpoint committee will review regis-
try data on the causes of death and data from the Danish
National Patient Register concerning hospital admis-
sions; supplemental data will be requested from hospitals
and the GP if needed.
Cost effectiveness evaluation
Analysis will be based on national registries of health care
utilization and the outcomes of the clinical analysis and
undertaken from a health care sector perspective after 5
and 10 years of follow-up, respectively. The cost effective-
ness analysis will be based on all-cause mortality as the pri-
mary outcome and disease-specific mortality as a secondary
outcome [33]. The cost-utility analysis will be based on
quality adjusted life years using Danish preference weights
of the normal population [34]. In addition, the lifetime per-
spective will be analyzed in a separate decision analytic
model [35]. Finally, pilot studies involving 1,000 randomly
selected women aged 65–74 years and 1,000 men
aged 60–64 will be performed for health economic cost ef-
fectiveness modeling, in order to evaluate the conse-
quences of choosing these alternative target groups.
Ethical considerations
The medical examination will not cause any notable in-
conveniences or any definite risk. However, several large
epidemiological studies do suggest that radiation expos-
ure is associated with a slightly increased risk of cancer.
The best-studied cohort is the Japanese atomic bomb
survivor cohort. In a group exposed to radiation doses
of 5 – 100 mSv (a mean dose of 29 mSv), 4,406 solid
cancers were observed between 1958 and 1998, an ex-
cess of 81 solid cancers over the expected cancer rates.
This finding corresponds to an excess relative risk of
2 % [36]. No large studies involving medically exposed
adult cohorts are available, but a linear no-threshold
model has been considered. Thus, there may be no min-
imal radiation dose for an increased cancer risk, and the
risk increases linearly with the radiation dose. The aver-
age dose in our pilot study was 1 mSv [10]. For compari-
son, a typical dose of a mammogram is 0.2 mSv, the
annual background radiation dose in Denmark is 3 mSv,
and the average annual limit for radiation workers is
20 mSv [37]. According to the Danish National Committee
on Biomedical Research Ethics, a radiation dose of 0.1–
1 mSv to subjects under 50 year of age is associated with an
overall cancer risk in the magnitude of 1 in 100,000, and to
subjects older than 50 years, the radiation dose can be in-
creased by a factor of 5 to 10.
An offer for screening is known to reduce the quality
of life in the period leading up to the examination, but
the effect fades out in the absence of a positive finding.
It is unclear if a sustained reduction in the quality of life
is caused by the diagnosis itself or by comorbidity, but
the reduction is modest. Such “secondary side effects”
should be weighed against the prophylactic benefits that
might be achieved. A more serious problem in connec-
tion with the detection of aneurysms is the risk of death
caused by rupture of the aneurysm in conservatively
treated cases and perioperative deaths in cases where the
AAA might not have otherwise ruptured. This serious
ethical problem has no solution at present. We hope
that the studies with the planned biobank will facilitate
the development of a prognostic model.
Participants are mature men who are fully capable of
deciding whether to accept or reject the invitation, and
efforts have been made to provide a comprehensive ex-
planation of the study in the invitation.
Participants will be given time to consider their participa-
tion before deciding and are informed that they may bring
a companion, preferably a spouse/partner. In case of a posi-
tive finding, all participants will be offered an in-depth out-
patient interview as soon as possible. At the consultation,
Diederichsen et al. Trials  (2015) 16:554 Page 6 of 10
information will be given concerning the prognosis of the
positive finding and the need and benefit of prophylactic
measures. Statin treatment may increase the risk of diabetes
mellitus by 9 % (from 1.12 % to 1.22 % per year, adapted
from [38]). However, this risk is outperformed by the de-
creased risk of development of ischemic heart disease and
stroke by 30 % and 19 %, respectively (from 1.29 % to
1.00 % per year, and 0.55 % to 0.45 %, respectively, adapted
from [6]). Aspirin increases the risk of hemorrhage (from
0.07 % to 0.10 % per year) while decreasing the risk of CVD
(from 0.57 % to 0.51 % per year) [39]. The side effects
should be weighed against the risk reduction achieved. A
specific dilemma is the situations in which AAA is diag-
nosed and requires surgery, which carries a 1–3 % mortal-
ity risk, which should be weighed against the mortality
risk of approximately 90 % in AAA ruptures. When there
is an AAA surgery indication, the patient is informed of
the surgical risks and the risks of conservative treatment,
and a surgery date is set. One of the project managers has
experience in performing this function.
As a part of the study, a biobank will be organized.
This will be maintained for a 15-year period, and data
will subsequently be anonymous.
The protocol was approved by the Regional Scientific
Ethical Committee for Southern Denmark (S-20140028)
and the Data Protection Agency. It is conducted in ac-
cordance with the Declaration of Helsinki. Written in-
formed consent was obtained from each participant.
Discussion
The target group was determined by cynical consider-
ations of where the benefit was most likely to be highest
and most cost effective. Younger men were excluded, as
85 % of all cardiovascular deaths in Denmark occur after
the age of 65, the CAC scores, prevalences of aneurysms
and PAD increase rapidly after the age of 65, and screen-
ing for AAA has proven beneficial and cost effective in
men aged 65–74.
Women were excluded, as although they increasingly
die of CVD, it happens in general much later in life.
Thus CVD-related morbidity and mortality in this age
group is much higher in men — at least in Denmark —
and screening for AAA is cost effective in men in this
age group, while the prevalence in Danish women is 1–2
out of 1,000 and thus most likely to be cost ineffective.
However, the decision was difficult, and random samples
of women aged 65–74 and men aged 60–64 will be in-
vited in order to be able to estimate the benefit and
cost-effectiveness by modeling.
The trial compares active systematic preventive action
based upon finding of subclinical arterial lesions in the
coronary and lower limb arteries and the aortoiliacal ves-
sels as well as classic risk factor management. If some are
started by GPs without DANCAVAS criteria fulfilled, we
consider that to be similar to what is happening in the
control group. Consequently, it seems difficult to identify
others in high risk without expensive angiographic exami-
nations. Consequently, it could be questioned whether if
no lesions were diagnosed, that existing preventive medi-
cation could be stopped. However, we decided on a prag-
matic approach, as the patient could be worried if
preventive actions were taken away, and his GP could be-
come hostile for DANCAVAS recommendation concern-
ing other patients of the GP.
We decided to define hypercholesterolemia as >
8 mmol/L, which is relatively high. However, if any lesion
was detected, statins were recommended regardless of
plasma cholesterol. If no lesion is observed when a patient
has very high cholesterol at the age of 70, it could be de-
bated whether they should be treated at all, so we chose
this high level.
Financial and budgetary administration
The participating sites will fund the CT scans and room
facilities, while the study organization will cover the
costs for the study staff, hemoglobin, HbA1c, lipid, CK,
and ALAT measurements, as well as biobanking. The
obtained funding will be administered by OUH, where
the project secretary will be located. Expenses are pri-
marily paid for by funds from public and private dona-
tions and sponsorships. The project managers have no
economic affiliation to any of the foundations. Partici-
pants will not receive any remuneration or reimburse-
ments for transportation costs.
Expected number of examinations, operations, and visits
Four screening sites are established in Svendborg,
Odense, Vejle, and Silkeborg. At each site, 37 men will
be invited at 10-minute intervals on each of the days
scheduled for screening with a total of 284 screening
days. If each site can provide two weekly screening days,
enrollment may be completed within one year. Individ-
uals with positive findings will attend a 20-minute out-
patient appointment for information and initiation of
preventive actions instruction. Two days a week is as-
sumed needed for these outpatient appointments.
One in every 10 cases of AAA is expected to need re-
ferral for surgical assessment; among these referred
cases, 90 % are expected to undergo surgery. These sur-
gical cases are estimated to add 1–2 AAA operations to
the surgery schedule per month per department. The
vascular surgery departments do not anticipate any
problems with the handling of these cases due to the
prevention of emergency cases.
Organization
The Executive Committee, consisting of the cardiologist
Axel Diederichsen, biochemist Lars M. Rasmussen, and
Diederichsen et al. Trials  (2015) 16:554 Page 7 of 10
the vascular surgeon Jes S. Lindholt, will handle the de-
cisions regarding the administration, budget, overall
organization, data, use of biobank, and principles for
authorships.
The Steering Committee will consist of the members of
the executive committee, Michael Hecht Olsen as the
expert in cardiovascular risk factors, Hans Mickley as an
expert in ischemic heart disease, Jesper Hallas as the
pharmaco-epidemiologist, a senior statistician who will
be collaborating with Jesper Hallas, the health economist
Rikke Søgaard, and one representative from each screen-
ing site. All practical issues concerning the screening,
follow-up, biobank, and data sampling will be handled
by the steering committee. In addition, the steering com-
mittee will participate as authors in the reporting of the
primary endpoints.
The Advisory Board consists of the following inter-
national experts who have various special interests in spe-
cific areas: cardiologist Peter Libby (Brigham and Women’s
Hospital, Boston, MA, USA), cardiologist Raimund Erbel
(West-German Heart Center Essen, Germany), statistician
Simon Thompson (MRC statistical unit, Cambridge,
UK), health economist Dorthe Gyrd-Hansen (University
of Southern Denmark), translational CV researcher Jean B
Michel (Hôpital Xavier Bichat, Paris, France), and trans-
lational AA researcher Guo Ping Shi (Brigham and
Women’s Hospital, Boston, USA).
Data registration
Data registration will be electronic and based on nu-
meric codes established by the project secretary and kept
in a locked room at CIMA. The database will be stored
on an internal hospital drive to avoid the risk of data loss
in case of a technical failure. Only the project secretary
and the independent data review committee members
will have access to the complete database. However, the
executive and steering committees will have access to
data concerning the invited group to secure follow-up
and allow for observational studies.
Strengths and limitations
There are no exclusion criteria in the study, and this im-
plies that patients with known CVD, such as former
stroke and myocardial infarction, may also be invited to
participate. This might be superfluous, because these in-
dividuals have documented CVD, and preventive care
should have already been established. However, these pa-
tients do have an increased prevalence of aneurysms and
may therefore benefit from the screening [40–42]. This
possible benefit will be explored in detail in subgroup
analyses. Another limitation is the lack of a non-imaging
experimental group. Thus, in case there are benefits to
the screening, we will be unable to differentiate whether
the benefit was due to the imaging findings or due to
treatment of classical risk factors, such as hypertension.
However, in many of these elderly subjects, primary
medical intervention is controversial, and the decision is
left to the individual subjects with the GP minimizing
the difference from the usual care. Additionally, in this
study of males aged 65–74 years, the major problem of
unexpected sudden deaths among young men is not ad-
dressed. However, as the population gets older, this
study will provide important knowledge about initiating
prevention among retired men.
Feasibility
The two executive committee members, Axel Diederich-
sen and Jes Lindholt, have previously organized and im-
plemented similar population studies concerning CAC,
AAA, and PAD [10, 43, 44].
In addition, several experts assist the members of the
executive committee: Michael Hecht Olsen has experi-
ence investigating risk factors in large clinical trials and
population-based studies. Hans Mickley has important
scientific knowledge in ischemic heart disease. Rikke
Søgaard has experience in evaluating and modeling the
cost effectiveness of screening programs. Jesper Hallas is
experienced in exploiting the unique Danish pharmaco-
epidemiological possibilities, while local experts are se-
curing practical feasibility of the project at the specific
screening sites. Lars Melholt Rasmussen is an expert in
biochemistry and biobanking and, as the head of the
Elitary Research Centre CIMA, he will perform the inde-
pendent administration of this complex project.
Meetings with the advisory board, which consists of a
multidisciplinary team of internationally recognized re-
searchers, covering cardiovascular screening, health eco-
nomics, advanced statistics, and translational cardiovascular
medicine will design and plan the optimal method of data
sampling including biosamples for scientific investigation.
The design and plan will be implemented by the scientific
committee and, finally, managed, analyzed, and reported by
the specific writing committees organized by the executive
committee.
Trial status
In October 2014, the pilot study started at the site in
Odense University Hospital to test the screening
methods and logistics. At New Year 2014/2015, the pro-
gram was running smoothly. However, every sixth ap-
pointment needs to be left unbooked in order to
minimize severe delays. By May 2015, 1,200 participants
had been included.
Two afternoon/evenings weekly are used for the
screening. The participants visit four different rooms
during the session. In the first room general information
about the study is given, and informed consent together
with a short questionnaire interview is obtained. In the
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second room measurements of brachial and ankle blood
pressure as well as abdominal ultrasound scanning for
AAA for validation through the pilot study are sched-
uled. In the third room the CT scans and measurements
of CAC score and aortic diameters are performed. The
heart rhythm is recorded from the telemetry of the CT
scanner and subsequently noted. In the fourth and last
room the required blood samples are drawn.
All data are collected in the web database, and a pro-
gram performs an automatic interpretation. In patients
with minor “positive” findings (CAC above the median,
small aneurysm or PAD) and inadequate preventive
medical treatment, a consultation with a nurse is ar-
ranged. During this consultation, the patients are advised
to adopt a healthful lifestyle and medication is pre-
scribed. Patients with major “positive” findings (like large
aneurysms or atrial fibrillation) are referred for further
diagnostic examinations (contrast CT scan and/or echo-
cardiography) and a consultation with a physician and
surgery if needed.
The remaining patients are informed of the “negative”
findings in writing and encouraged to see their GP if po-
tential undiagnosed hypertension, diabetes mellitus, or
hypercholesterolemia are suspected. The GPs will be in-
formed electronically of all negative and positive results
and the initiated actions.
The second screening site is expected to start in June
2015 and the third in September 2015, while the start-
up time of the fourth site is still unknown.
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